<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04074460</url>
  </required_header>
  <id_info>
    <org_study_id>16/144</org_study_id>
    <nct_id>NCT04074460</nct_id>
  </id_info>
  <brief_title>Volatile Anaesthesia and Perioperative Outcomes Related to Cancer Feasibility Study</brief_title>
  <acronym>VAPOR-C</acronym>
  <official_title>Volatile Anaesthesia and Perioperative Outcomes Related to Cancer (VAPOR-C): A Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peter MacCallum Cancer Centre, Australia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Melbourne Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Alfred</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peter MacCallum Cancer Centre, Australia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicentre, prospective randomized, active-controlled feasibility trial of volatile-based&#xD;
      anaesthesia vs. propofol-based total intravenous anaesthesia to investigate the impact of&#xD;
      anaesthesia on long-term (i.e. 5-years) patient cancer outcomes in patients undergoing&#xD;
      elective major cancer surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to assess the feasibility of conducting a phase IV, multi-centre,&#xD;
      single-blinded, randomized control trial (VAPOR-C (Main)).&#xD;
&#xD;
      Primary aims To measure the ability to recruit eligible patients into the study.&#xD;
&#xD;
      To measure the ability to successfully deliver each of the two anaesthetic techniques&#xD;
      (volatile-based general anaesthesia and propofol-based anaesthesia) according to the research&#xD;
      protocol.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">August 27, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Patients are blinded to the anaesthetic type given. Statistician also blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>To measure the ability to recruit eligible patients into the study.</measure>
    <time_frame>18 months</time_frame>
    <description>The study protocol will be assessed as feasible if a recruitment rate of at least 75% is achieved.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To measure the ability to successfully deliver each of the two anaesthetic techniques (volatile-based general anaesthesia and propofol-based anaesthesia) according to the research protocol.</measure>
    <time_frame>18 months</time_frame>
    <description>The study protocol will be assessed as feasible if a successful delivery rate of at least 90% is achieved.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To identify that all sites can capture data within the electronic case report form (eCRF) and utilize the electronic data capturing system (REDCap).</measure>
    <time_frame>18 months</time_frame>
    <description>All missing data to be recorded including reason for missing data, where available. Quantitative and qualitative analysis of reasons for missing data will be analysed by : Number of fields with missing data (percentage) and reason for missing data ( qualitative descriptor). Fields with &gt;1 missing data point will be analysed for reasons for failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To test the efficiency of the centralized patient enrolment and computer randomization system.</measure>
    <time_frame>18 months</time_frame>
    <description>Number of events of failed randomisation will be recorded on eCRF (under 'treatment of subjects&quot;). Quantitative analysis of failed randomisation (reported as %) as well as descriptive reason for failure will be recorded and analysed. This will allow shortcomings in the use of the computer-generated centralised randomisation program to be identified and ratified.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Cancer, Breast</condition>
  <condition>Cancer Colorectal</condition>
  <condition>Cancer Prostate</condition>
  <condition>Cancer, Lung</condition>
  <condition>Cancer Melanoma Skin</condition>
  <condition>Cancer, Other</condition>
  <arm_group>
    <arm_group_label>Propofol (TIVA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Propofol-based total intravenous anaesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Volatile</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Volatile-based (isoflurane, sevoflurane or desflurane) general anaesthesia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>General Anaesthesia</description>
    <arm_group_label>Propofol (TIVA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>isoflurane, sevoflurane or desflurane</intervention_name>
    <description>General Anaesthesia</description>
    <arm_group_label>Volatile</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
          -  Age 18-80 years&#xD;
&#xD;
          -  Elective surgery&#xD;
&#xD;
          -  Major cancer surgery expecting to last two or more hours, for:&#xD;
&#xD;
          -  Breast (mastectomy or segmentectomy plus sentinel node dissection)&#xD;
&#xD;
          -  Colorectal&#xD;
&#xD;
          -  Lung&#xD;
&#xD;
          -  Prostate&#xD;
&#xD;
          -  Melanoma (excision of melanoma plus lymph node dissection AND/OR skin flap&#xD;
             construction&#xD;
&#xD;
          -  Other major cancer surgeries (e.g. oesophagectomy, head and neck cancer, etc.)&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Palliative surgery for end-stage disease with no curative intent&#xD;
&#xD;
          -  Emergency surgery&#xD;
&#xD;
          -  Extensive comorbid disease, i.e. American Society of Anesthesiologists (ASA) Score &gt; 4&#xD;
&#xD;
          -  Age &lt;18 or &gt;80 years old&#xD;
&#xD;
          -  Refusal or inability to provide valid informed consent&#xD;
&#xD;
          -  Risk of severe postoperative nausea and vomiting (PONV risk score &gt;3)&#xD;
&#xD;
          -  Previous allergy or contraindication to either anaesthetic medication&#xD;
&#xD;
          -  Indication for gas induction of anaesthesia&#xD;
&#xD;
          -  Currently enrolled in another clinical trial unless agreed by the coordinating&#xD;
             principal investigator and site principal investigator that co-enrolment can occur.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Research Manager</last_name>
    <phone>+61 3 85596654</phone>
    <email>vapor-c@petermac.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Manager</last_name>
      <phone>+61 3 85596654</phone>
      <email>vapor-c@petermac.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 15, 2019</study_first_submitted>
  <study_first_submitted_qc>August 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2019</study_first_posted>
  <last_update_submitted>August 27, 2019</last_update_submitted>
  <last_update_submitted_qc>August 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>major surgeries lasting &gt;2 hours</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
    <mesh_term>Desflurane</mesh_term>
    <mesh_term>Isoflurane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

